Associations between RNA-Binding Motif Protein 3, Fibroblast Growth Factor 21, and Clinical Outcome in Patients with Stroke.
FGF21
RBM3
body weight
clinical outcome
stroke
temperature
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Feb 2022
11 Feb 2022
Historique:
received:
04
01
2022
revised:
07
02
2022
accepted:
09
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
RNA-binding motif protein 3 (RBM3) is a cold-induced marker of good functional outcome of ischemic stroke that is promising as a protective target. Fibroblast growth factor 21 (FGF21) is an obesity- and temperature-related hormone that upregulates the expression of RBM3, which is beneficial as a recombinant treatment and has been tested under different experimental pathological conditions, including stroke. However, the interaction between RBM3 and FGF21 has not yet been tested for clinical stroke conditions. In a sample of 66 stroke patients, we analyzed the associations between the FGF21 and RBM3 serum concentrations on admission and at 72 h, body weight, maximum temperature during the first 24 h, and the outcome of patients at 3 months. We also analyzed their association with biomarkers of obesity (adiponectin and leptin) and inflammation (interleukin-6 (IL-6) and interleukin (IL-10)). Higher concentrations of FGF21 on admission and RBM3 at 72 h were associated with good outcomes. Serum FGF21 and RBM3 were directly related to body mass index and inversely related to the maximum temperature during the first 24 h. We found a positive association between the FGF21 concentrations in obese patients with leptin and a negative correlation with adiponectin in non-obese participants. This clinical study demonstrates the association between RBM3 and FGF21 levels and the outcome of stroke patients. Although further investigations are required, these data support the pharmacological induction of RBM3 as a promising protective therapy.
Sections du résumé
BACKGROUND
BACKGROUND
RNA-binding motif protein 3 (RBM3) is a cold-induced marker of good functional outcome of ischemic stroke that is promising as a protective target. Fibroblast growth factor 21 (FGF21) is an obesity- and temperature-related hormone that upregulates the expression of RBM3, which is beneficial as a recombinant treatment and has been tested under different experimental pathological conditions, including stroke. However, the interaction between RBM3 and FGF21 has not yet been tested for clinical stroke conditions.
METHODS
METHODS
In a sample of 66 stroke patients, we analyzed the associations between the FGF21 and RBM3 serum concentrations on admission and at 72 h, body weight, maximum temperature during the first 24 h, and the outcome of patients at 3 months. We also analyzed their association with biomarkers of obesity (adiponectin and leptin) and inflammation (interleukin-6 (IL-6) and interleukin (IL-10)).
RESULTS
RESULTS
Higher concentrations of FGF21 on admission and RBM3 at 72 h were associated with good outcomes. Serum FGF21 and RBM3 were directly related to body mass index and inversely related to the maximum temperature during the first 24 h. We found a positive association between the FGF21 concentrations in obese patients with leptin and a negative correlation with adiponectin in non-obese participants.
CONCLUSIONS
CONCLUSIONS
This clinical study demonstrates the association between RBM3 and FGF21 levels and the outcome of stroke patients. Although further investigations are required, these data support the pharmacological induction of RBM3 as a promising protective therapy.
Identifiants
pubmed: 35207221
pii: jcm11040949
doi: 10.3390/jcm11040949
pmc: PMC8875775
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Spanish Ministry of Economy and Competitiveness
ID : SAF2017-84267-R
Organisme : Xunta de Galicia
ID : IN607D2020/03
Organisme : Instituto de Salud Carlos III
ID : ICI19/00032 and PI20/01014
Organisme : Instituto de Salud Carlos III
ID : Sara Borrell (CD/20/00054), PFIS (FI18/00071), and Miguel Servet contracts (CPII17/00027 and CPII19/00020)
Références
J Neurotrauma. 2018 Sep 1;35(17):2091-2103
pubmed: 29648978
Mol Pharmacol. 2008 Aug;74(2):403-12
pubmed: 18467542
Exp Neurol. 2019 Jul;317:34-50
pubmed: 30802446
Cell Metab. 2007 Jun;5(6):415-25
pubmed: 17550777
Cell Physiol Biochem. 2016;38(3):1218-25
pubmed: 26982498
Peptides. 2007 Dec;28(12):2382-6
pubmed: 17996984
Neuroscience. 2015 Oct 1;305:268-78
pubmed: 26265550
Cell Mol Life Sci. 2016 Oct;73(20):3839-59
pubmed: 27147467
Exp Neurol. 2019 Oct;320:113007
pubmed: 31295445
J Cereb Blood Flow Metab. 2011 Apr;31(4):1085-92
pubmed: 20978518
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Stroke. 2018 Dec;49(12):3039-3049
pubmed: 30571410
Stroke. 2017 Jan;48(1):219-221
pubmed: 27856954
Mol Metab. 2015 May 01;4(7):519-27
pubmed: 26137439
PLoS One. 2016 Aug 24;11(8):e0161458
pubmed: 27556928
Front Neurol. 2017 Jun 12;8:244
pubmed: 28659854
Exp Gerontol. 2021 Apr;146:111214
pubmed: 33385482
Neurochem Int. 2012 Apr;60(5):495-505
pubmed: 22361061
Biochem Biophys Res Commun. 2011 Oct 14;414(1):170-4
pubmed: 21945934
Neurosci Lett. 2006 Jan 23;393(1):56-9
pubmed: 16229951
Nat Rev Endocrinol. 2020 Nov;16(11):654-667
pubmed: 32764725
Mol Neurobiol. 2019 Apr;56(4):2314-2327
pubmed: 30022432
J Muscle Res Cell Motil. 2018 Apr;39(1-2):35-40
pubmed: 30051360
Int J Obes (Lond). 2017 Oct;41(10):1570-1578
pubmed: 28588304
J Neuroinflammation. 2020 Aug 31;17(1):257
pubmed: 32867781
Stroke. 1998 Dec;29(12):2455-60
pubmed: 9836750
Front Physiol. 2019 Feb 05;10:37
pubmed: 30804796
Dev Neurosci. 2018;40(4):325-336
pubmed: 30399610
Nat Rev Neurosci. 2012 Feb 22;13(4):267-78
pubmed: 22353781
J Clin Endocrinol Metab. 2008 Sep;93(9):3627-32
pubmed: 18559909
J Cereb Blood Flow Metab. 2019 Dec;39(12):2355-2367
pubmed: 31566073
Annu Rev Physiol. 2016;78:223-41
pubmed: 26654352
Sci Rep. 2019 Jan 24;9(1):630
pubmed: 30679672
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1197-204
pubmed: 19738035
Brain Commun. 2020 Jun 04;2(2):fcaa078
pubmed: 33585816
Stroke. 2016 Sep;47(9):2386-96
pubmed: 27491739
Transl Stroke Res. 2019 Dec;10(6):639-649
pubmed: 30980283
Ther Hypothermia Temp Manag. 2019 Mar;9(1):13-47
pubmed: 30802174
Front Pharmacol. 2021 Apr 22;12:671131
pubmed: 33967812
Lancet Neurol. 2019 May;18(5):439-458
pubmed: 30871944
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Life Sci Alliance. 2021 Feb 9;4(4):
pubmed: 33563652
Curr Neurovasc Res. 2019;16(1):19-26
pubmed: 30706812
Scand J Trauma Resusc Emerg Med. 2015 Jun 05;23:42
pubmed: 26043908
Obes Rev. 2016 Oct;17(10):989-1000
pubmed: 27405510